Inventor · disambiguated record
Brian Stuart Lucas
Also filed as: LUCAS BRIAN · LUCAS BRIAN S · LUCAS BRIAN STUART
14 granted patents·19 pending applications·40 citations·filing 2003–2025
90Inventor score
Top patents by PatentIndex Score
33 records- 0194US9623018B2Processes of making and crystalline forms of a MDM2 inhibitorAMGEN INC·Filed 2016·Granted Apr 18, 2017·6 cites·28 claims
- 0291US10100063B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2016·Granted Oct 16, 2018·8 cites·12 claims
- 0388US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0488US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0587US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 0685US9801867B2Processes of making and crystalline forms of a MDM2 inhibitorAMGEN INC·Filed 2016·Granted Oct 31, 2017·2 cites·30 claims
- 0784US2023301974A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2023·Application pending·0 cites
- 0881US11203601B2Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereofBROAD INST INC·Filed 2018·Granted Dec 21, 2021·2 cites·41 claims
- 0980US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 1076US6875866B2Process for synthesis of D1 receptor antagonistsSCHERING CORP·Filed 2003·Granted Apr 5, 2005·9 cites·20 claims
- 1175US2022280496A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2021·Application pending·0 cites
- 1274US11001598B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted May 11, 2021·0 cites·8 claims
- 1374US10836779B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Nov 17, 2020·0 cites·8 claims
- 1474US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 1574US2024279197A1Nrf2 activatorBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 1674US2020281912A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2019·Application pending·0 cites
- 1773US9873701B2Heterocyclic compounds and their usesAMGEN INC·Filed 2014·Granted Jan 23, 2018·1 cites·16 claims
- 1870US2018092898A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2017·Application pending·0 cites
- 1968US2025295647A1Processes of making and crystalline forms of a mdm2 inhibitorAMGEN INC·Filed 2024·Application pending·0 cites
- 2067US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 2165US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 2264US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 2363US2021387960A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 2462US12486289B2Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereofBROAD INST INC·Filed 2021·Granted Dec 2, 2025·0 cites·31 claims
- 2561US2022048884A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 2658US2021340107A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 2755US2019389830A1Nrf2 activatorBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 2852US10968181B2NRF2 activatorBIOGEN MA INC·Filed 2017·Granted Apr 6, 2021·0 cites·24 claims
- 2952US2019389836A1Nrf2 activatorBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 3046US9873704B2Heterocyclic compounds and their usesAMGEN INC·Filed 2016·Granted Jan 23, 2018·0 cites·3 claims
- 3145US2025313563A1Glycogen synthase kinase 3 inhibitors and uses thereofBROAD INST INC·Filed 2025·Application pending·0 cites
- 3243US2010331306A1Heterocyclic compounds and their usesAMGEN INC·Filed 2010·Application pending·0 cites
- 3338US11465963B2Tetrahydronaphthalene derivatives useful as Nrf2 activatorsBIOGEN MA INC·Filed 2018·Granted Oct 11, 2022·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Brian Stuart Lucas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →